<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00748618</url>
  </required_header>
  <id_info>
    <org_study_id>382-08-FB</org_study_id>
    <nct_id>NCT00748618</nct_id>
  </id_info>
  <brief_title>Vitamin D Replacement After Kidney Transplant</brief_title>
  <official_title>Vitamin D Replacement After Kidney Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitamin D deficiency accelerates vascular risk progression after kidney transplant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial will assess the following aims:&#xD;
&#xD;
        1. Time to plateau vitamin D concentrations after initiating vitamin D supplements&#xD;
&#xD;
        2. Safety of vitamin D replacement based on serum and urine calcium&#xD;
&#xD;
        3. Effect of vitamin D on PTH concentration in individuals with elevated parathyroid&#xD;
           hormone&#xD;
&#xD;
        4. Effect of vitamin D on markers of insulin resistance and inflammation&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare efficacy and safety of two vitamin D supplements of these doses in normalizing vitamin D concentrations.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The ability of vitamin D to reduce parathyroid hormone concentration or change markers of vascular risk, insulin resistance, and/or inflammation, as well as its affect on urine calcium excretion.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">165</enrollment>
  <condition>Kidney Transplantation</condition>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard vitamin treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50,000 I.U. of vitamin D3</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>vitamin D3</intervention_name>
    <description>10,000 I.U./wk of vitamin D3 orally for 6 months</description>
    <arm_group_label>1</arm_group_label>
    <other_name>D3, vitamin D</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>vitamin D3</intervention_name>
    <description>50,000 I.U./wk of vitamin D3 orally for 6 months</description>
    <arm_group_label>2</arm_group_label>
    <other_name>D3, vitamin D</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Kidney transplant more than 6 months ago&#xD;
&#xD;
          -  19 years or older&#xD;
&#xD;
          -  25-OH vitamin D ≤35 ng/ml&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Estimated GFR&lt;30 ml/min/1.73m²&#xD;
&#xD;
          -  Previous small bowel or lung transplant&#xD;
&#xD;
          -  Pancreas transplant less than 6 months ago&#xD;
&#xD;
          -  Cancer or any condition that would change their weight dramatically in the near future&#xD;
             such as malabsorption&#xD;
&#xD;
          -  Willing to return for testing every two months&#xD;
&#xD;
          -  Women who are pregnant or &lt; 6 weeks postpartum&#xD;
&#xD;
          -  Calcium &gt; 10.5 mg/dl&#xD;
&#xD;
          -  Phosphate &gt; 4.8 mg/dl&#xD;
&#xD;
          -  Drinking more than 2 alcohol drinks a day or 14 drinks per week&#xD;
&#xD;
          -  History of parathyroid surgery&#xD;
&#xD;
          -  Known granulomatous disease&#xD;
&#xD;
          -  Taking any seizure medication that affects vitamin D&#xD;
&#xD;
          -  Taking zempler ® and/or Rocaltrol ®&#xD;
&#xD;
          -  History of kidney stones in the past 20 years&#xD;
&#xD;
          -  Not on a stable dose of bisphosphonate for the past three months&#xD;
&#xD;
          -  Planning on a pancreas transplant within the next year&#xD;
&#xD;
          -  In any other research study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer L Larsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 4, 2008</study_first_submitted>
  <study_first_submitted_qc>September 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2008</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>Jennifer Larsen, MD</investigator_full_name>
    <investigator_title>Vice Chancelor of Research</investigator_title>
  </responsible_party>
  <keyword>Kidney transplantation (KTX)</keyword>
  <keyword>Vitamin D deficiency</keyword>
  <keyword>Cardiovascular Disease (CVD)</keyword>
  <keyword>Vascular risk</keyword>
  <keyword>Parathyroid hormone (PTH)</keyword>
  <keyword>Carotid intima media thickness (CIMT)</keyword>
  <keyword>Insulin resistance (IR)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

